Malignant neoplasm of esophagus
|
0.600 |
Biomarker
|
disease |
BEFREE |
Linc01014 regulates gefitinib resistance in oesophagus cancer via EGFR-PI3K-AKT-mTOR signalling pathway.
|
31785047 |
2020 |
Malignant neoplasm of esophagus
|
0.600 |
Biomarker
|
disease |
BEFREE |
Nimotuzumab is a humanized monoclonal antibody against epidermal growth factor receptor (EGFR), the efficacy of nimotuzumab added to nCRT for esophageal cancer is uncertain.
|
31258850 |
2019 |
Malignant neoplasm of esophagus
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Presently, the single nucleotide polymorphisms (SNPs) of EGFR/PLCE1 genes and their associations with EC survival remain unclear.
|
31209807 |
2019 |
Malignant neoplasm of esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Results indicated that PT shows more effective antitumor activity as compared with Pan both on EGFR-overexpressed KYSE-450 and KYSE-150 esophageal cancer cells, especially on KYSE-450 cells.
|
30596104 |
2018 |
Malignant neoplasm of esophagus
|
0.600 |
Biomarker
|
disease |
BEFREE |
GE11 surface modification onto GO significantly increased the cellular uptake of GO in EGFR overexpressed oesophageal cancer cells (KYSE-30 and EC109 cells) than that of normal cells, indicating the EGFR targeting effects of Ori@GE11-GO.
|
30183382 |
2018 |
Malignant neoplasm of esophagus
|
0.600 |
Biomarker
|
disease |
BEFREE |
<sup>111</sup>In-labelled polymeric nanoparticles incorporating a ruthenium-based radiosensitizer for EGFR-targeted combination therapy in oesophageal cancer cells.
|
29808844 |
2018 |
Malignant neoplasm of esophagus
|
0.600 |
Biomarker
|
disease |
BEFREE |
These phase 3 trial results point to little benefit to current EGFR-targeted agents in an unselected patient population, and highlight the need for predictive biomarkers in the treatment of esophageal cancer.
|
28687830 |
2017 |
Malignant neoplasm of esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
This cancer-targeted design of Se NPs provides a new strategy for synergistic treating of cancer with higher efficacy and reduced side effects, introducing GE11-Ori-Se NPs as a candidate for further evaluation as a chemotherapeutic agent for EGFR over-expressed esophageal cancers.
|
29019267 |
2017 |
Malignant neoplasm of esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In this study, we first evaluated EGFR gene and protein expression in 70 Chinese EC patient tumor samples collected during surgery.
|
28881608 |
2017 |
Malignant neoplasm of esophagus
|
0.600 |
Biomarker
|
disease |
BEFREE |
A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer.
|
28498434 |
2017 |
Malignant neoplasm of esophagus
|
0.600 |
Biomarker
|
disease |
BEFREE |
Methods A prespecified, blinded molecular analysis of Cancer Esophagus Gefitinib trial tumors was conducted to compare efficacy of gefitinib with that of placebo according to EGFR copy number gain (CNG) and EGFR, KRAS, BRAF, and PIK3CA mutation status.
|
28537764 |
2017 |
Malignant neoplasm of esophagus
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results indicated that miR-133a could inhibit the MEK/ERK pathway to promote cell apoptosis and enhance radio-sensitivity by targeting EGFR in EC..
|
27933650 |
2017 |
Malignant neoplasm of esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We also observed a significant increase in ERCC1 expression, and decrease in p53 and EGFR expression, in EC-9706 cells treated with SNX-2112 (P < 0.05), indicating the regulation of EC by SNX-2112.
|
27420968 |
2016 |
Malignant neoplasm of esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Real-time quantitative polymerase chain reaction technology (RT-PCR) was used to detect the expression of VEGF, HER-2, and EGFR mRNA in esophageal squamous cancer tissue of 60 cases and 30 cases of VEGF, HER-2, and EGFR mRNA in esophageal cancer adjacent tissues, and analyze its relationship with clinicopathological features.
|
26099724 |
2015 |
Malignant neoplasm of esophagus
|
0.600 |
Biomarker
|
disease |
BEFREE |
Expression and prognostic influence of NF-κB and EGFR in esophageal cancer.
|
26681028 |
2015 |
Malignant neoplasm of esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Both YAP1 and EGFR are overexpressed in resistant esophageal cancer tissues compared with sensitive esophageal cancer tissues.
|
25739674 |
2015 |
Malignant neoplasm of esophagus
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer.
|
23377570 |
2014 |
Malignant neoplasm of esophagus
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
Microtubule inhibition causes epidermal growth factor receptor inactivation in oesophageal cancer cells.
|
23174948 |
2013 |
Malignant neoplasm of esophagus
|
0.600 |
Biomarker
|
disease |
BEFREE |
More than 50% EGFR-positive EsC and MPM cells were resistant to EGFR-TKI, and susceptibility to EGFR-TKI growth-inhibitory effect correlated positively with expression of E-cadherin (epithelial gene marker) and negatively with mesenchymal gene markers.
|
23749888 |
2013 |
Malignant neoplasm of esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In this report, the effect of PYM on EGFR expression in human esophageal cancer cells and the therapeutic efficacy of the combination of PYM and cetuximab on esophageal cancer xenograft were investigated.
|
22311160 |
2012 |
Malignant neoplasm of esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We report the outcome in a series of esophageal cancer patients treated at our center and the results of a retrospective analysis of epidermal growth factor receptor (EGFR) expression and EGFR/HER2 gene copy numbers taken as possible prognostic and predictive factors.
|
23052161 |
2012 |
Malignant neoplasm of esophagus
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Over-expression of epidermal growth factor receptor in esophageal cancer is associated with poor prognosis.
|
22555809 |
2012 |
Malignant neoplasm of esophagus
|
0.600 |
Biomarker
|
disease |
BEFREE |
We evaluated the antitumor effects of lapatinib, a dual tyrosine kinase inhibitor which simultaneously inhibits EGFR and HER2, 5-fluorouracil (5-Fu) alone and in combination on esophageal cancer cells.
|
22293713 |
2012 |
Malignant neoplasm of esophagus
|
0.600 |
Biomarker
|
disease |
CTD_human |
Targeting the human EGFR family in esophagogastric cancer.
|
21468131 |
2011 |
Malignant neoplasm of esophagus
|
0.600 |
Biomarker
|
disease |
CTD_human |
The EGFR CA repeat genetic polymorphism may act as a valuable molecular predictor of clinical outcome of esophageal cancer after CCRT and esophagectomy, especially in those with good response to CCRT.
|
21298351 |
2011 |